Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal first quarter financials before market open on August 6.

Analysts have a consensus C$31.97 12-month price target on the company, via a total of 15 analysts, with one analyst having a strong buy rating, and three analysts have a buy rating. Nine analysts have a hold rating and two analysts have a strong sell rating. The street high comes from MKM Partners with a C$51 price target, and the lowest target comes from Bryan Garnier with a C$18 price target.

12 analysts have revenue estimates for the first quarter. The mean between all 12 is C$149.04 million; this number has been revised slightly downwards from C$175.35 million at the start of the year. The street high is C$163.70 million while the lowest sits at C$115.43 million.

Five analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 25%, with this number being revised slightly downwards from 30.67% at the start of the year. Street high goes to Stifel-GMP with a 28% estimate and the lowest sits at 20%.

Onto EBITDA estimates, there are currently 13 analysts who have first quarter EBITDA estimates. The mean is currently (C$64.51) million, with this number being lower at the start of the year. Street high goes to Oppenheimer with a (C$45) million EBITDA estimate and the lowest being a (C$83) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Nutrien Sees Consensus Price Target Improvement Following Raised Guidance

On June 21st, Nutrien (TSX: NTR) raised their first half 2021 earnings per share guidance...

Wednesday, June 23, 2021, 03:36:00 PM

Amazon: Canaccord Cuts Targets On “Macroeconomic Uncertainty And Inflation”

Amazon.com, Inc. (Nasdaq: AMZN) last week reported its third-quarter financial results. The company continued the...

Wednesday, November 2, 2022, 03:47:00 PM

Microsoft: Q3 Earnings Consensus Estimates

Microsoft (NASDAQ: MSFT) will be reporting their fiscal third quarter financials on April 27th after...

Monday, April 26, 2021, 04:02:00 PM

Ayr Wellness: Cantor Halves Price Target On Weak Q1 Results

On May 26, Ayr Wellness (CSE: AYR.A) reported its first quarter financial results. The company...

Saturday, May 28, 2022, 05:08:00 PM

Couche-Tard: Canaccord Reiterates $51 Price Target After Q3 Results

On November 23rd, Alimentation Couche-Tard Inc. (TSX: ATD.B) announced its fiscal second quarter results. The...

Friday, November 26, 2021, 04:32:00 PM